Background
==========

Autism spectrum disorder (ASD) manifests significant heterogeneity in part because of the interaction of underlying genetic \[[@B1]-[@B3]\], neurobiological, and environmental factors \[[@B4],[@B5]\] during early brain development. This heterogeneity presents one of the main obstacles to the development of effective treatments for ASD. The complex genetics of ASD suggest that it is a large set of related disorders with diverse mechanisms; however, many of the etiologies implicated in ASD may converge on a few common pathways. Further research on single gene disorders associated with ASD such as tuberous sclerosis complex (TSC) and fragile X syndrome (FXS) may lead to an understanding of common dysfunction at the cellular or circuit level for a majority of ASD. In a recent survey of over 14,000 individuals under age 35 with ASD in a Boston area hospital, Kohane and colleagues reported that the prevalence of genetic disorders of FXS and TSC in individuals with ASD were 0.5% and 0.8% \[[@B6]\]. Conversely, 30% and 50-61% of patients with FXS and TSC present ASD core symptoms, respectively \[[@B7],[@B8]\]. If such shared pathophysiology exists, then treatments developed for a target in one disorder might be applicable to others. Mouse models for ASD serve an increasingly important role in providing a pre-clinical test of promising pharmacological therapeutics \[[@B9],[@B10]\]. Inactivating mutation in *Tsc2* (*Tsc2*+/− mice) showed defects in axon guidance \[[@B11]\] and cognitive deficits such as impaired water maze performance \[[@B12]\], and mice with *Fmr1*-knockout (KO) presented impairments in long-term depression, hyperactivity, anxiety-like, and unusual social behaviors \[[@B13]\]. Therefore, determining the degree to which there are shared molecular mechanisms in these models will inform clinical trials, particularly those that address populations with genetically heterogeneous causes of ASD.

Although several cellular mechanisms may be implicated (reviewed in Fatemi et al. \[[@B14]\]), accumulating data support a role for the PI3K-mTOR signaling cascade in several genetic causes of ASD. Evidence for the PI3K-mTOR pathway first emerged from TSC \[[@B15],[@B16]\] and mutations in the *PTEN* gene associated with ASD and macrocephaly \[[@B17]-[@B19]\]. Later, investigation of copy number variants (CNV) in autistic individuals identified that PI3K-mTOR pathway-related genes were located in CNV hotspots \[[@B20]\]. These findings have led to the hypothesis that overactivation of the mTOR pathway could lead to abnormal synaptic function owing to an excess of protein synthesis at the synapse \[[@B21]\]. Genetic evidence that directly implicates a translation initiating factor, EIF4E, which is a downstream target of mTOR, in ASD has provided further support for this hypothesis \[[@B22]\]. Interestingly, exposure to teratogens such as valproate *in utero* can lead to ASD in children \[[@B23]\], and valproate can also modulate this signaling pathway \[[@B24]\], suggesting that environmental factors associated with ASD can also play a role in PI3K-mTOR pathway regulation \[[@B25]\]. More recently, studies have found that PI3K-mTOR signaling is upregulated in mouse models of FXS, one of the most common genetic causes of ASD \[[@B26]-[@B28]\].

Together, the aforementioned findings suggest that an upregulated PI3K-mTOR signaling cascade might be a common mechanism in ASD and therefore would potentially be a promising drug target. Indeed, clinical trials using inhibitors of mTOR are already in progress in patients with TSC. We hypothesized that if the PI3K-mTOR signaling pathway is dysregulated in various causes of ASD, then these disorders should present with a similar gene expression profile signature. We chose to analyze TSC and FXS, two Mendelian disorders highly associated with ASD. Better understanding of similarities and differences of the cellular and molecular defects leading to abnormal neurological function in these two disorders is essential to the development of new therapies for ASD. Here, we used mouse models available for both genetic disorders to investigate the similarities and differences between gene expression profiles in the brain and blood cells.

Methods
=======

Murine models of fragile X syndrome and tuberous sclerosis
----------------------------------------------------------

To identify molecular signatures of each mouse model of ASD, we performed gene expression profiling on cerebellum and peripheral blood collected from two mouse models and compared to wild-type (WT) controls. We used cerebellum where the most consistent abnormalities were reported in the patients with ASD \[[@B14]\]. Post-mortem studies have shown a reduced number of Purkinje cells (PC), and several neuroimaging studies reported enlarged cerebella in ASD \[[@B29],[@B30]\]. The cerebellum is also implicated in social interaction \[[@B31]\], and the loss of *Tsc1* from cerebellar PC was associated with autistic-like behaviors \[[@B32]\]. Additionally, we profiled whole blood from the same individual mouse to compare with the gene expression changes in cerebellum.

All male C57BL/6 congenic *Fmr1*-KO mice and *Tsc2+/−* mice with mixed 129/SvJae-C57BL/6 J background have been previously described \[[@B33],[@B34]\]. We profiled *Tsc2+/−* mice since homozygous *Tsc2* KO was embryonic lethal. The mice were killed at 8--10 weeks of age following the institutional animal care and use committee (IACUC) euthanasia criteria (the Boston Children's Hospital IACUC animal protocol no. 12-07-2227R). For the *Fmr1*-KO model, 5 KO and 5 WT mice were profiled, and for the *Tsc2+/−* model 3 transgenic and 3 WT mice were profiled. Paired blood and cerebellum samples were prepared for gene expression profiling.

Genome-wide gene expression profiling using microarrays
-------------------------------------------------------

A total of 250 ng RNA was processed using established Affymetrix protocols for the generation of biotin-labeled cRNA, and the hybridization, staining, and scanning of arrays were performed. Briefly, total RNA was converted to double-stranded cDNA using a T7 primer and biotin-labeled cRNA was then generated from the cDNA by in vitro transcription. The cRNA was quantified (using A260) and fragmented. Fragmented cRNA was hybridized to the Affymetrix Mouse Gene ST 1.0 array and scanned on an Affymetrix GeneChip scanner 3000 at 2.5 μm resolution \[[@B35]\]. Microarray data are available at the Gene Expression Omnibus database (GSE40630).

Validation of gene expression changes using quantitative RT-PCR
---------------------------------------------------------------

Total RNA was extracted using TRIzol according to the manufacturer's instruction. The RNA amount was measured using the Nanodrop (Thermo Scientific); 100 ng of total RNA was reversed transcribed using a cDNA reverse transcription kit with random primers (Applied Biosystems). SyBr Green PCR Master Mix (Applied Biosystems) was used to amplify and detect signals from cDNA with 1 mM gene-specific primers. Amplified signals were collected by the 7300HT Fast Real-Time System (Applied Biosystems) and normalized to *Gapdh*. Primer sequences used for this study were *Gapdh* forward 5′-tgtgtccgtcgtggatctga-3′ reverse 5′-cctgcttcaccaccttcttga-3′, *Fmr1* forward 5′-ggtcaaggaatgggtcgagg-3′, reverse 5′-agtcgtctctgtggtcagat-3′, *Tsc2* forward 5′-cagtgtcgaccagctgtctt-3′, reverse 5′-tcacgctgtctggtcttgtc-3′, *Eps811* forward 5′-cagctacaacacgagaagcg-3′, reverse 5′-ccgaaccttccaccatttgc-3′ and *Grin3a* forward 5′-ctgaaacctgggtgtgaggt-3′, and reverse 5′-aatgctgttcccacacaaca-3′.

Microarray analysis
-------------------

All microarrays were normalized together at the probe-level using a quantile method, and the Affymetrix Probe Logarithmic Intensity ERror (PLIER) model was used to calculate the absolute gene expression levels as previously described \[[@B35]\]. We fitted a linear model of the tissue (i.e., blood vs. cerebellum) and treatment (i.e., transgenic vs. WT) as predicting variables to each probe set. Two murine models were analyzed separately as different background strains were used. Differentially expressed genes in each murine model were compared to the differentially expressed genes between the wild types of two models. The false discovery rate (FDR) was calculated using Storey and Tibshirani's method \[[@B36]\]. We did not use non-parametric tests such as the Wilcoxon rank sum test because of the granularity of the test statistics with a small number of samples per group.

We identified enriched pathways using the Gene Set Enrichment Analysis (GSEA) \[[@B37]\]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of size 15--500 were used for pathway analysis. Due to the relatively small number of samples in each group, we randomly sampled gene sets of equal size for each KEGG pathway to calculate the background distribution of enrichment scores. This procedure was done with 2,000 random drawings, thus the minimum permutation p-value was 0.0005. We used permutation *p*-value 0.05 as the significance threshold for GSEA, and corresponding FDRs were described. To identify the core set of genes that accounts for the gene set's enrichment signal, we used leading edge analysis as described in Subramanian et al. \[[@B37]\] where a leading edge subset was defined as the subset of genes that gave the maximum enrichment score. These genes were the topmost correlated genes with phenotype in a gene set.

To compare differentially expressed genes with the list of known ASD candidate genes as curated in the SFARIgenes 2.0 database (<http://gene.sfari.org/>) \[[@B38]\], we mapped mouse genes to human homologs using the Mouse Genome Informatics (MGI) Web database (<http://www.informatics.jax.org>) and performed hypergeometric tests to check the significance of overlap.

Results
=======

Distinct gene expression changes define Fmr1 and Tsc2 transgenic models
-----------------------------------------------------------------------

A total of 107 and 115 probe sets were significantly changed in *Fmr1*-KO and *Tsc2+/−* mice compared to corresponding WT littermates, respectively (uncorrected *p*-value \< 0.01). Not surprisingly, *Fmr1* was the most significantly downregulated gene in *Fmr1*-KO (*p*-value 8.85 × 10^-6^, corresponding FDR 0.29). We used nominal *p*-values estimated from a linear model less than 0.01 to rank significant probe sets because multiple testing correction procedures did not make any gene significant. The expression levels of 16 out of 107 significant probe sets (15.0%) in *Fmr1*-KO mice and 58 out of 115 significant probe sets (50.4%) in *Tsc2+/−* mice did not show a significant difference between blood and brain. We used an agglomerative hierarchical clustering with the significant probe sets for each model to explore the similarity of gene expression profiles in two genotypes and across tissue types. Samples were clearly separated by tissue type and then by genotype (Figure [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B). Interestingly, 71% of significant probe sets in *Fmr1*-KO mice were highly expressed in cerebellum compared to blood (Figure [1](#F1){ref-type="fig"}A). For the *Tsc2+/−* model, the average expression levels of 63 out of 115 probe sets (57.5%) were higher in cerebellum (Figure [1](#F1){ref-type="fig"}B). Differentially expressed genes with statistical scores are listed in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1 (*Fmr1-*KO vs. WT) and Additional file [1](#S1){ref-type="supplementary-material"}: Table S2 (*Tsc2+/−* vs. WT).

![**Agglomerative hierarchical clustering of blood and brain samples. (A)** Hierarchical clustering of *Fmr1*-KO and wild-type samples. One hundred seven differentially expressed transcripts (nominal *p*-value \< 0.01) are used for hierarchical clustering of transcripts (*rows* in the heatmap) and samples (*columns* in the heatmap). The gene expression levels are normalized across samples, and *red* (upregulated) and *blue* (downregulated) are color coded according to the *bottom color bar. Color keys* on the top of the heatmap denote tissue type and transgenic model. By far the most pronounced clustering is by tissue type. Within the blood samples, the two mice strains are clearly separated. **(B)** Hierarchical clustering of *Tsc2* +/− and wild-type samples. One hundred fifteen significant transcripts are used for cluster analysis. Two mice strains formed separate clusters in each tissue type. The tissue specificity is not significant for the differentially expressed transcripts in *Tsc2* +/− mice, whereas a majority of differentially expressed genes are highly expressed in cerebellum of *Fmr1*-KO mice (*lower right cluster* in the heatmap of Figure [1](#F1){ref-type="fig"}A).](2040-2392-5-16-1){#F1}

We compared the gene expression profiles of WT mice since *Tsc2+/−* mice had 129/SvJae-C57BL/6 J backgrounds compared to C57BL/6 congenic backgrounds of *Fmr1*-KO mice. A total of 1,486 probes sets were differentially expressed between two WT strains. Seven probe sets, representing five genes, *Cog7, Cc2d1a, Smurf1, Sec31a*, and *AU040320*, overlapped with the differentially expressed genes in *Fmr1*-KO vs. WT comparison. For the differentially expressed genes in *Tsc2+/−* vs. WT comparison, 13 probe sets (representing 9 genes: *Fhad1, Pgam5, Cts8, Piwil4, Tmem101, Heatr7a, Mucl1, 2210404J11Rik*, and *Fam181b*) were significantly different between two WT mice strains.

Epidermal growth factor (EGF) receptor pathway substrate 8-like 1 *(Eps811)* (Affymetrix probe set ID: 10549655) was the only gene that was significant in both murine models. *Eps811* was upregulated in Tsc2+/− mice, but downregulated in *Fmr1-*KO mice. Post hoc two-group comparison of the transgenic model to WT for each tissue showed that *Eps811* was upregulated in blood (Welch's *t*-test *p*-value 0.07) and brain (Welch's *t*-test *p*-value 0.06) of Tsc2+/− mice, while it was downregulated in blood (Welch's *t*-test *p*-value 0.015) of *Fmr1-*KO mice. Downregulation of *Eps811* in brain of *Fmr1-*KO was not significant (Welch's *t*-test *p*-value 0.38). The homolog of *Eps811* in human, *EPS8L1* is a member of EPS8-related proteins that play an important role in actin remodeling in response to EGF \[[@B39]\], and *EPS8* is one of the reported targets of FMRP \[[@B40]\]. Interestingly, Stamatakou and colleagues reported that Eps8 loss of function impaired the structural and functional plasticity of synapses induced by long-term potentiation in primary rat hippocampal neurons \[[@B41]\]. Phenotypically, *Eps8-*KO mice have impaired learning and memory, and excessive synaptic growth and abnormal spine morphology were observed in the hippocampus \[[@B42]\]. In human samples, the average expression of *EPS8* in fusiform gyri was significantly lower among the patients with ASD compared to controls \[[@B42]\]. Although *Eps8* itself was not significantly changed in our study, *EPS8* family genes are interesting candidates for further investigation. Thus, we performed qRT-PCR of *Eps8* in brain samples of two murine models.

Of the differentially expressed genes, several were also found in the expert curated database of autism candidate genes. Of these, *Chd7, Fmr1*, and *Tmlhe* were differentially expressed in *Fmr1*-KO mice, and *Oxtr* and *Taf1c* were significantly changed in *Tsc2+/−* mice. The differentially expressed genes were not significantly enriched for known ASD candidate genes in human (hypergeometric test *p*-value 0.48 for *Fmr1-*KO and 0.70 for *Tsc2+/−*).

Validation of differentially expressed genes using quantitative RT-PCR
----------------------------------------------------------------------

Quantitative RT-PCR for individual genes was used to further confirm the results of the expression profiling in the brain samples used for the initial analysis. As expected, *Fmr1* gene expression was significantly decreased in *Fmr1*-KO mice as compared to controls (average 5.24-fold downregulated, Welch's *t*-test *p*-value 0.025), while *Fmr1* was unchanged in *Tsc2*+/− mice (Welch's *t*-test *p*-value 0.70). *Tsc2* gene expression showed a trend of decreased expression in both *Tsc2*+/− and *Fmr1*-KO mice as compared to WT mice that did not reach significance (average fold change 1.12 and 1.31 downregulation, Welch's *t*-test *p*-value 0.55 and 0.27, respectively). We previously found a significant reduction of Tsc2 protein in cortical neurons of *Tsc2+/−* mice \[[@B11]\]; however, *Tsc2* mRNA expression was not significantly downregulated. Further, our results confirm that *Eps8l1* exhibited a three-fold increase in *Tsc2*+/− animals as compared to WT mice (average 3.15-fold upregulation, Welch's *t*-test *p*-value 0.06). However, *Eps8l1* expression shows a decreased trend---an average 1.26 fold downregulation---in *Fmr1*-KO compared to WT similar to that observed in the expression profiling but not significantly changed (Welch's *t*-test *p*-value 0.74).

We observed significant downregulation of subtype 3a of the N-methyl-D-aspartate receptor gene (*Grin3a*) in the blood of *Fmr1*-KO mice (uncorrected *p*-value 0.0098). *Grin3a* was not significant in brain with microarray data; however, a quantitative RT-PCR analysis of the same samples showed a significant downregulation of this gene in *Fmr1*-KO brain (5.69-fold downregulated, Welch's *t*-test *p*-value 0.046).

Enriched biological pathways in blood and brain of the two mouse models
-----------------------------------------------------------------------

We explored whether similar sets of biological pathways were perturbed in both models using GSEA \[[@B37]\] as there was only one overlapping gene---*Eps8l1*---between the two lists of differentially expressed genes in *Fmr1*-KO and *Tsc2+/−* mice. The genes that contributed to making a pathway significant were identified using leading edge analysis. First, all genes were ranked by a per-gene signal-to-noise ratio that was defined as mean difference divided by the sum of standard deviation of each group. Then a running sum was calculated for each gene set. Beginning with the top-ranked gene, the running sum increased when a gene in a gene set was found and decreased otherwise. The enrichment score (ES) was defined to be the largest value of the running sum, and the genes that maximized ES were defined as the leading edge subset.

Two pathways related to cytokine and complement-mediated signaling, cytokine-cytokine receptor interaction (HSA04060, FDR \< 0.0005) and complement and coagulation cascades (HSA04610, FDR \< 0.0005), were the most significantly enriched pathways in *Fmr1*-KO brain (Table [1](#T1){ref-type="table"}). Neuroactive ligand receptor interaction (HSA04080, FDR \< 0.0005), long-term potentiation (HSA04720, FDR 0.0023), gap junction (HSA04540, FDR 0.0429), and axon guidance (HSA04360, FDR 0.048) were also enriched in *Fmr1*-KO brain. Among the signaling pathways, the PI3K signaling pathway (HSA04070) was changed in both brain (FDR 0.042) and blood (FDR 0.05) of *Fmr1*-KO mice. Eight genes were in the leading edges of the two tissues (see Methods). These were *Dgkb, Dgkg, Dgkh, Inpp4b, Inpp5a, Itpr3, Plcb4,* and *Prkca*. Glutamate metabolism (HSA00251) was also enriched in *Fmr1*-KO brain (FDR 0.043).

###### 

**Enriched pathways in blood and brain of*Fmr1*knockout mice**

  **KEGG categories**                 **Name**                                              **SIZE**   **NES**   **NOM p-val**   **FDR q-val**
  ----------------------------------- ---------------------------------------------------- ---------- --------- --------------- ---------------
  ***Brain***                                                                                                                           
  Nervous system                      HSA04080 Neuroactive ligand receptor interaction        223       2.34       \< 0.0005        0.0000
                                      HSA04720 Long-term potentiation                          62       −2.15      \< 0.0005        0.0023
                                      HSA04540 Gap junction                                    77       −1.75      \< 0.0005        0.0429
                                      HSA04360 Axon guidance                                  125       −1.81      \< 0.0005        0.0480
  Immune system                       HSA04060 Cytokine-cytokine receptor interaction         212       2.72       \< 0.0005       \< 0.0005
                                      HSA04610 Complement and coagulation cascades             47       2.32       \< 0.0005       \< 0.0005
                                      HSA04650 Natural killer cell mediated cytotoxicity       95       1.70        0.0015          0.0379
                                      HSA04612 Antigen processing and representation           42       1.67        0.0049          0.0397
                                      HSA04640 Hematopoietic cell lineage                      66       2.09       \< 0.0005        0.0004
  Signaling pathways                  HSA01430 Cell communication                             118       2.14       \< 0.0005        0.0004
                                      HSA04630 Jak-STAT signaling pathway                     137       2.07       \< 0.0005        0.0005
                                      HSA04070 Phosphatidylinositol signaling system           65       1.77        0.0029          0.0420
                                      HSA04910 Insulin signaling pathway                      126       1.80       \< 0.0005        0.0455
  Metabolism                          HSA00150 Androgen and estrogen metabolism                33       1.84        0.0043          0.0118
                                      HSA00590 Arachidonic acid metabolism                     39       1.81        0.0017          0.0147
                                      HSA00361 γ-hexachlorocyclohexane degradation             17       1.69        0.0118          0.0370
                                      HSA00020 Citrate cycle                                   25       1.93        0.0023          0.0375
                                      HSA00592 α-linolenic acid metabolism                     15       1.70        0.0127          0.0392
                                      HSA00251 Glutamate metabolism                            30       1.87        0.0038          0.0430
  Folding, sorting, and degradation   HSA04120 Ubiquitin mediated proteolysis                  36       1.78        0.0039          0.0453
                                      HSA04130 Snare interactions in vesicular transport       29       1.84       \< 0.0005        0.0450
  ***Blood***                                                                                                                           
  Signaling pathways                  HSA04070 Phosphatidylinositol signaling system           65       1.78       \< 0.0005        0.0500

Eight pathways were significantly enriched in *Tsc2+/−* brain, while 11 pathways were enriched in *Tsc2+/−* blood (Table [2](#T2){ref-type="table"}). Pathways associated with the immune system were significantly enriched in both blood and brain. Ribosome (HSA03010, FDR \< 0.0005), cytokine-cytokine receptor interaction (HSA04060, FDR \< 0.0005), and oxidative phosphorylation (HSA00190, FDR \< 0.0005) were the most significant pathways in the brain, and the ribosome pathway was also significantly deregulated in *Tsc2+/−* blood (FDR 0.0468). In the *Tsc2+/−* brain, cytokine-cytokine receptor interaction (FDR \< 0.0005) and hematopoietic cell linage (HSA04640, FDR 0.0389) were significant, while the Toll-like receptor signaling pathway (HSA04620, FDR 0.0016) and B-cell receptor signaling pathway (HSA04662, FDR 0.0072) were significant in *Tsc2+/−* blood. None of the differentially expressed genes between two WT strains was a member of significant pathways that we identified above.

###### 

**Enriched pathways in blood and brain of*Tsc2+/−*mice**

  **KEGG categories**     **Name**                                                     **SIZE**   **NES**   **NOM p-val**   **FDR q-val**
  ----------------------- ----------------------------------------------------------- ---------- --------- --------------- ---------------
  ***Brain***                                                                                                                      
  Immune system           HSA04060 Cytokine-cytokine receptor interaction                212       2.37       \< 0.0005       \< 0.0005
                          HSA04640 Hematopoietic cell lineage                             66       1.75       \< 0.0005        0.0389
  Signaling pathways      HSA04010 MAPK signaling pathway                                241       −1.92      \< 0.0005        0.0431
                          HSA01430 Cell communication                                    118       2.15       \< 0.0005        0.0007
  Translation             HSA03010 Ribosome                                               66       3.21       \< 0.0005       \< 0.0005
  Metabolism              HSA00563 Glycosylphosphatidylinositol anchor biosynthesis       21       −1.85       0.0017          0.0444
                          HSA00190 Oxidative phosphorylation                             110       2.75       \< 0.0005       \< 0.0005
                          HSA00980 Metabolism of xenobiotics by cytochrome P450           35       1.77       \< 0.0005        0.0379
  ***Blood***                                                                                                                      
  Nervous system          HSA05010 Alzheimer's disease                                    26       1.92       \< 0.0005        0.0034
  Immune system           HSA04620 Toll-like receptor signaling pathway                   94       2.00       \< 0.0005        0.0016
                          HSA04662 B cell receptor signaling pathway                      60       1.85       \< 0.0005        0.0072
  Cell growth and death   HSA04110 Cell cycle                                            107       −2.31      \< 0.0005        0.0005
                          HSA04210 Apoptosis                                              73       1.78        0.0006          0.0181
  Translation             HSA03010 Ribosome                                               66       1.68        0.0026          0.0468
  Metabolism              HSA01032 Glycan structures degradation                          29       2.16       \< 0.0005        0.0000
                          HSA00530 Aminosugars metabolism                                 29       1.95        0.0007          0.0035
                          HSA00531 Glycosaminoglycan degradation                          17       1.92       \< 0.0005        0.0043
                          HSA00511 Other glycan degradation                               15       1.88        0.0007          0.0047
                          HSA00600 Sphingolipid metabolism                                31       1.69        0.0064          0.0473

Common signature of *Fmr1* and *Tsc2* transgenic models
-------------------------------------------------------

Cytokine-cytokine receptor interaction pathway, hematopoietic cell linage, and cell communication were enriched in brain gene expression profiles of both *Fmr1*-KO and *Tsc2+/−* mice (Figure [2](#F2){ref-type="fig"}). We performed leading edge analysis to find core genes that made a pathway significant, although each gene was not necessarily differentially expressed. For the cytokine-cytokine receptor pathway (N = 212), 105 and 106 genes were the core genes in *Tsc2+/−* and *Fmr1*-KO brain data sets. *Il7r* was the only gene that showed marginal significances in both data sets (post-hoc Welch's *t*-test *p*-values 0.011 and 0.013 in *Tsc2+/−* and *Fmr1*-KO brain profiles, respectively). The same gene was also the only common significant gene for the hematopoietic cell lineage pathway. Thirty-two genes were in common between the leading edges of cell communication for *Fmr1*-KO and *Tsc2+/−* brain; however, no genes were significantly differentially expressed. Interestingly, *Tsc2* gene expression was downregulated in *Fmr1*-KO blood (post-hoc Welch's *t*-test *p*-value 0.0045).

![**Enriched pathways in*Fmr1*-KO and*Tsc2+/−*models of ASD, found using the Gene Set Enrichment Analysis (GSEA).***Red* (upregulated) and *blue* (downregulated) squares in the matrix represent enriched pathways for each data set (false discovery rate ≤ 0.05). Two immune system pathways (cytokine-cytokine receptor signaling pathway and hematopoietic cell lineage) and one signaling pathway (cell communication) were significant in the brain gene expression profiles of both mice models.](2040-2392-5-16-2){#F2}

Discussion
==========

We hypothesized that *Fmr1*-KO and *Tsc2+/−* mice would have similar gene expression profiles. In contrast, our findings indicate that different gene expression signatures define these two monogenic mouse models of ASD. Global expression profiles of the two models examined were distinct, such that only one gene---*Eps8l1*---was in common. This is a particularly surprising result since translational dysregulation as well as aberrant synaptic protein synthesis associated with both disorders has been proposed as one possible pathway leading to autistic phenotypes, including cognitive impairment \[[@B21]\]. Our data indicate that FXS and TSC may have very distinct brain and blood cellular phenotypes despite the fact that both syndromes result in similar behavioral and cognitive symptoms.

Nonetheless, we did find that the cytokine and complement signaling pathways are differentially regulated in both mouse models although the specific genes affected within these pathways were different. The immune system has been implicated in ASD in multiple ways, but the exact mechanism of the interaction between the immune system and genetic disorders that result in an increased risk of autism has not been well studied. Modulation of the immune system may not be completely unexpected since the TSC-mTORC1 pathway regulates inflammatory responses after bacterial stimulation in monocytes, macrophages, and primary dendritic cells \[[@B43]\], and this pathway contributes to cytokine upregulation in response to endotoxins \[[@B44]\]. However, this is of particular interest in light of a recent study that showed that immune activation during gestation can markedly worsen the neurological phenotype of *Tsc2+/−* mouse pups \[[@B45]\]. Similarly, preliminary observations indicate that plasma protein levels of a number of cytokines differ between individuals with and without FXS. Furthermore, differences in cytokine and other immune-signaling genes were observed between the FXS group with autism and the FXS group without autism \[[@B46]\]. On the other hand, Yuskaitis and colleagues investigated the peripheral immune system of *Fmr1*-KO mice, but did not find any differences in either the T-cell population at basal and stimulated status or the proinflammatory cytokines TNFα and IFNγ at basal and stimulated status \[[@B47]\]. How the loss of FMRP leads to changes in the immune system, however, remains unclear.

Accumulating evidence over the last few years indicates that the TSC and FMRP pathways interact. However, precisely how these pathways interact remains an open question. On the one hand, FMRP can be phosphorylated by S6K, an enzyme downstream of TSC \[[@B48]\]. On the other hand, mTOR, the kinase inhibited by the TSC2 protein, has increased activity in *Fmr1*-KO neurons \[[@B26]\], and FMRP-deficient cells display increased activity of PI3K, an enzyme upstream of TSC proteins \[[@B27]\]. Recently Auerbach et al. reported that the synaptic dysfunction in the CA1 region of the hippocampus of *Tsc2+/−* mice was opposite to that of *Fmr1*-KO mice \[[@B49]\]. In fact, manipulating the mGluR receptors with positive allosteric modulators was sufficient to rescue this defect in *Tsc2+/−*, while inhibiting the mGluR receptors was necessary in the case of *Fmr1*-KO mice. Finally, a genetic cross of the *Tsc2+/−* and *Fmr1*-KO mice was similar to WT in CA1 synaptic physiology and contextual learning. These results argue that loss of Tsc2 and Fmr1 have some opposite cellular phenotypes, which can be rescued in a double knockout. However, the mechanisms by which Tsc2 and Fmr1 result in opposite synaptic phenotypes is not yet clear. In post-hoc analysis, we found that *Tsc2* gene expression was downregulated in *Fmr1*-KO blood (Welch's *t*-test *p*-value 0.0045). Thus, in the *Tsc2+/− Fmr1*-KO mice, the Tsc2 expression level may be closer to WT and may contribute to the rescue of the synaptic physiology. This finding points to another level of interaction between the FMRP and Tsc2 functions in the cell. Future studies are required to understand whether *Fmr1* loss leads to changes in Tsc2 mRNA via transcriptional or post-transcriptional regulation.

Similarities between the proposed roles of TSC1/2 and FMRP proteins in regulation of protein synthesis have led to the popular hypothesis that hyperactive mTOR signaling is pathogenic in both FXS and TSC. Our results indicate the gene expression dysregulation differs markedly in the two conditions. This is consistent with the previously reported changes in neuronal morphology in each of these models. Neurons deficient in *Tsc1* or *Tsc2* display lower dendritic spine density in contrast to *Fmr1*-KO neurons \[[@B50]\], which have increased spine density \[[@B51]\]. At the biochemical level there are also some important differences. In *TSC1/2*-null cells, mTORC1-dependent negative feedback mechanisms exist to dampen the activation of upstream components of the network such that Akt activation is decreased \[[@B52]\]. However, in *Fmr1*-KO neurons, Akt activity is enhanced \[[@B27]\]. While mTORC1 may be activated because of loss of either Tsc1/2 or FMRP, the neuronal phenotype and gene expression profiles may be altered by changes in the activation of other signaling pathways. Such differences have implications for targeted treatment options of the two distinct genetic conditions.

The mouse models we have explored have been developed as models of ASD with known divergent genetic etiologies. The overall divergence in gene expression dysregulation in these two models does not rule out shared downstream effects, and indeed we observed an overlapping dysregulation of the cytokine signaling pathway. Nonetheless, it does suggest that a multiplicity of therapeutics will have to be developed for the varied mechanisms contributing to the increasingly fine-grained distinctions between the etiologies of ASD.

We could identify similar sets of biological pathways enriched in both tissues. In the *Fmr1-*KO mice, the PI3K signaling pathway was dysregulated in both blood and brain, while the ribosome pathway was dysregulated in both tissues of *Tsc2 +/−.* With the two mouse models, we also could identify biological pathways that were positively correlated with genetic background in both tissues. Previous studies demonstrated that peripheral blood expression signatures could be used to classify the clinical conditions of brain disorders \[[@B35],[@B53]\]. Likewise, our results suggest that peripheral blood signatures could be used to identify genotypes as well as some transcriptional changes present in brain.

The current study is limited by the different background strains of *Fmr1*-KO and *Tsc2+/−* mice and by the small sample size. The differentially expressed genes between two WT background strains overlapped with the significant genes in each murine model -- 5 for *Fmr1*-KO and 9 for *Tsc2+/−*. Although 1,486 probe sets were significantly differentially expressed between WT mice of two different backgrounds, none of these genes was a member of the significant pathways that characterized *Fmr1*-KO and *Tsc2+/−* mice in blood and brain. Due to the small sample size, we did not have enough statistical power for microarray experiments to detect and compare relatively low-expressed genes. Further study using the same background strain and increasing the sample size will be essential to confirm our findings, and using a more sensitive quantification method such as RNA-seq will improve sensitivity for low abundance transcripts. For the *Fmr1*-KO model, we did not include female mice heterozygous for *Fmr1* in this experiment. Heterozygous *Fmr1* female mice should exhibit genetic mosaicism due to random X-inactivation of one X chromosome during development. For this reason, most previous studies characterized male *Fmr1* KO models. Qin and colleagues performed an interesting comparison of male *Fmr1*-KO and homozygous and heterozygous KO in female mice \[[@B54]\]. They reported that only the homozygous mice had a deficit on the passive avoidance test, whereas both homozygous and heterozygous female mice exhibited hyperactivity and increased susceptibility to seizures. A follow-up experiment with both sexes and different dosages of *Fmr1* in female mice with a larger sample size would be ideal since a gender effect on global gene expression profiles should be considered when both sexes are included in the experiment.

Conclusions
===========

Contrary to our initial hypothesis that *Fmr1*-KO and *Tsc2+/−* mice would share a transcriptional signature, we found that the two mouse models presented distinct sets of differentially expressed genes. In retrospect, this is not surprising as multiple lines of evidence suggest that FXS and TSC are actually driven by opposite molecular phenotypes \[[@B49]\]. Despite these gene-level differences, however, we observed that cytokine signaling, cell communication, and hematopoietic cell lineage genes were differentially expressed in both mouse strains. Second, our results show that blood expression signatures mirror many aspects of the brain transcriptome. Specifically, several pathways were dysregulated in both the brain and blood of the two mouse models studied here. This confirmation is important for the future use of blood tissue to study neurodevelopmental disorders.
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###### Additional file 1: Table S1

The 107 transcripts were differentially expressed in *Fmr1*-KO mice compared to wildtype littermates. These probesets were used for the hierarchical clustering analysis as showed in Figure [1](#F1){ref-type="fig"}A. The transcript that was assigned for uncharacterized gene was designated as 'NA' with the Affymetrix probeset identifiers (AffyID). The p-value was estimated from a linear model using genotype and tissue as predicting variables for each probeset. The q-value denotes the false discovery rate that were calculated from the distribution of p-values using Storey and Tibshirani's (see Methods). Negative values in the fold changes represent down-regulated transcripts in transgenic mice. **Table S2.** The 115 transcripts were differentially expressed in *Tsc2* +/- mice compared to wildtype littermates. These probesets were used for the hierarchical clustering analysis as showed in Figure 1B. The transcript that was assigned for uncharacterized gene was designated as 'NA' with the Affymetrix probeset identifiers (AffyID). The p-value was estimated from a linear model using genotype and tissue as predicting variables for each probeset. The q-value denotes the false discovery rate that were calculated from the distribution of p-values using Storey and Tibshirani's (see Methods). Negative values in the fold changes represent down-regulated transcripts in transgenic mice.
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